ArticleJournal of the American Chemical Society2014
Rational design of CXCR4 specific antibodies with elongated CDRs.
Article in Journal of the American Chemical Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Stability convergence in natural antibodies with ultra-long hypervariable loops.Communications biology · 2025Article
- Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.Biomarker research · 2025Review
- Annotation of gene loci and analysis of expression diversity in sheep immunoglobulin.Frontiers in immunology · 2025Article
- A phase separation-fortified bi-specific adaptor for conditional tumor killing.Science China. Life sciences · 2024Article
- Programming cell-surface signaling by phase-separation-controlled compartmentalization.Nature chemical biology · 2022Article
- Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology.Antibodies (Basel, Switzerland) · 2022Review
- A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.Theranostics · 2022Article
- Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.Nature communications · 2021Article
- Broadly Neutralizing Bovine Antibodies: Highly Effective New Tools against Evasive Pathogens?Viruses · 2020Review
- Animal protein toxins: origins and therapeutic applications.Biophysics reports · 2018Article
- Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies.Science immunology · 2016Article
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.Angewandte Chemie (International ed. in English) · 2015Article
- Structural and genetic diversity in antibody repertoires from diverse species.Current opinion in structural biology · 2015Review
- An immunosuppressive antibody-drug conjugate.Journal of the American Chemical Society · 2015Article
- Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The bovine antibody (BLV1H12) which has an ultralong heavy chain complementarity determining region 3 (CDRH3) provides a novel scaffold for antibody engineering. By substituting the extended CDRH3 of BLV1H12 with modified CXCR4 binding peptides that adopt a β-hairpin conformation, we generated antibodies specifically targeting the ligand binding pocket of CXCR4 receptor. These engineered antibodies selectively bind to CXCR4 expressing cells with binding affinities in the low nanomolar range. In addition, they inhibit SDF-1-dependent signal transduction and cell migration in a transwell assay. Finally, we also demonstrate that a similar strategy can be applied to other CDRs and show that a CDRH2-peptide fusion binds CXCR4 with a K(d) of 0.9 nM. This work illustrates the versatility of scaffold-based antibody engineering and could greatly expand the antibody functional repertoire in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.